Hyper Baric Oxygen Therapy (HBOT) for Spontaneous Osteonecrosis of the Knee
Safety and Efficacy of Hyper Baric Oxygen Therapy (HBOT) in Patients Presenting With Spontaneous Osteonecrosis of the Knee
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yiftah Beer, MD
- Phone Number: 972-8-9779432
- Email: yiftah.beer@gmail.com
Study Locations
-
-
-
Zerifin, Israel, 70300
- Recruiting
- Assaf-Harofeh Medical Center
-
Contact:
- Yiftah Beer, MD
- Phone Number: 972-8-9779432
- Email: yiftah.beer@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age40-85 years
- Diagnosis of Spontaneous osteonecrosis of the knee (SONK)in last month, Stage 1 or 2 by MRI.
Exclusion Criteria:
- Hyperbaric treatment (HBOT) in the last 2 years.
- Any contraindication for HBOT
- Pregnancy.
- Inability to sign inform consent
- Any contraindication for MRI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Biological
6 weeks of HBO treatment as well as non weight bearing
|
|
|
Active Comparator: Control
non weight bearing
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy
Time Frame: 6 weeks
|
Pain Reduction
|
6 weeks
|
|
Safety
Time Frame: end of HBOT
|
Number of Participants with Adverse Events during HBOT
|
end of HBOT
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Reduction In AVN size by MRI
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Shai Efrati, MD, Assaf-Harofeh Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 91/12*1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spontaneous Osteonecrosis of the Knee
-
NCT00532220CompletedOsteonecrosis of the Knee | Bone Marrow Edema of the Knee
-
NCT06129214RecruitingOsteoarthritis, Knee | Rheumatoid Arthritis, Knee | Spontaneous Osteonecrosis of Knee
-
NCT07588269Not yet recruitingOsteonecrosis of the Jaw | Medication-related Osteonecrosis of the Jaw
-
NCT06917846CompletedOsteonecrosis Due to Drugs, Jaw | Osteonecrosis of the Jaw, Bisphosphonate Induced | Osteonecrosis of the Jaw, Bisphosphonate Related
-
NCT04584840RecruitingOsteonecrosis of the Jaw, Bisphosphonate Induced | Osteonecrosis of the Jaw, Bisphosphonate Related
-
NCT07585123Not yet recruitingOsteoradionecrosis of the Jaw | Medicine Related Osteonecrosis of the Jaw
-
NCT06457776RecruitingOsteonecrosis of the Jaw | Bisphosphonate-Associated Osteonecrosis | Bisphosphonate-Associated Osteonecrosis of the Jaw | Osteonecrosis Due to Drugs, Jaw | Osteonecrosis Due to Drug
-
NCT07464678CompletedMedication Related Osteonecrosis of the Jaw
-
NCT03040778Active, not recruitingAvascular Necrosis | Medication-related Osteonecrosis of the Jaw | Bisphosphonate-related Osteonecrosis of the Jaw
-
NCT06622421Not yet recruitingOsteonecrosis of the Jaw | Bisphosphonate-Associated Osteonecrosis of the Jaw | Osteonecrosis Due to Drug
Clinical Trials on Weight reduction
-
NCT01319162CompletedPolycystic Ovary Syndrome
-
NCT06081023CompletedObesity | Emotional Eating
-
NCT05927077Not yet recruiting
-
NCT07645105CompletedAbdominal Obesity-Metabolic Syndrome | Overweight , Obesity
-
NCT00852514CompletedHeart Diseases | Hypertension | Fluid Overload
-
NCT02868164WithdrawnNASH Related Decompensated Cirrhosis